10.68

0.28% -0.03

After Hours: 10.68

Amicus Therapeutics Inc (FOLD)

Overview News Price History Option Chain Financials Why FOLD Down? Discussions Forecast

Amicus Therapeutics Inc stock is traded at $10.68, with a volume of 2.20M. It is down -0.28% in the last 24 hours and down -8.01% over the past month. Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Previous Close:

$10.71

Open:

$10.64

24h Volume:

2.20M

Relative Volume:

0.90

Market Cap:

$3.18B

Revenue:

$423.49M

Net Income/Loss:

$-147.07M

P/E Ratio:

-16.69

EPS:

-0.64

Net Cash Flow:

$-88.03M

1W Performance:

-4.81%

1M Performance:

-8.01%

6M Performance:

-9.34%

1Y Performance:

-12.17%

1-Day Range:

$10.52

$10.80

1-Week Range:

$10.44

$11.35

52-Week Range:

$9.02

$14.57

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name

Amicus Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(215) 921-7600

Address

3675 MARKET STREET, PHILADELPHIA, NJ

Employee

517

Twitter

@amicusrx1

Next Earnings Date

2024-08-08

Latest SEC Filings

FOLD's Discussions on Twitter

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Apr-13-22	Resumed	Goldman	Neutral
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-15-21	Upgrade	Stifel	Hold → Buy
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight
Jul-19-21	Resumed	BTIG Research	Buy
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-02-21	Initiated	Stifel	Hold
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight
Dec-10-20	Downgrade	Citigroup	Buy → Neutral
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy
Feb-04-20	Resumed	Cantor Fitzgerald	Overweight
Nov-12-19	Reiterated	H.C. Wainwright	Buy
Jun-17-19	Initiated	H.C. Wainwright	Buy
Jun-05-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-05-19	Initiated	Janney	Buy
Jan-30-19	Initiated	Cantor Fitzgerald	Overweight
Oct-29-18	Initiated	Citigroup	Neutral
Aug-17-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-06-17	Resumed	Goldman	Neutral
Sep-13-17	Reiterated	Chardan Capital Markets	Buy
Aug-10-17	Reiterated	Chardan Capital Markets	Buy
Jan-24-17	Upgrade	Robert W. Baird	Neutral → Outperform
May-18-16	Initiated	BofA/Merrill	Buy
Apr-14-16	Initiated	Robert W. Baird	Neutral
Apr-12-16	Reiterated	Chardan Capital Markets	Buy
Sep-16-15	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-16-15	Reiterated	Chardan Capital Markets	Buy

View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

10:10 AM